

# Review of: "Ascorbic Acid Therapy in Hematological Malignancies - The Current Knowledge and Future Directions"

Seyed ahmad Rasoulinejad

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

To Dear Editorial Team It is a good manuscript suitable for publication. Before publication, I suggest to solve these comments: 1- in clinical trial table, I suggest to add a column regarding outcomes (or its last status). 2- In "What are the optimal doses, frequencies and duration of therapy?", it seems that AA is approved for hematopoietic malignancies. I suggest to re-write its headline title based on " clinical trial outcomes", not based on concentrations and doses in preclinical studies.